Can Bupropion 450 mg Daily Cause Atrial Fibrillation or Bradycardia?
Bupropion at 450 mg/day does not cause atrial fibrillation, but it can cause bradycardia requiring permanent pacemaker implantation, particularly with amiodarone and other antiarrhythmic drugs—not bupropion itself. The evidence provided addresses antiarrhythmic medications used for atrial fibrillation management, not bupropion's cardiovascular effects.
Direct Evidence on Bupropion's Cardiovascular Profile
Bupropion causes supine blood pressure elevation and tachycardia, not bradycardia or atrial fibrillation. 1
In 36 depressed patients with preexisting heart disease (left ventricular impairment, ventricular arrhythmias, or conduction disease), bupropion at a mean dose of 442 mg/day caused a rise in supine blood pressure but did not cause significant conduction complications, did not exacerbate ventricular arrhythmias, had a low rate of orthostatic hypotension, and had no effect on pulse rate. 1
Treatment was discontinued in 14% of patients due to adverse effects, including exacerbation of baseline hypertension in two patients—not bradycardia or atrial fibrillation. 1
Cardiovascular Toxicity in Overdose Settings
In overdose situations, bupropion causes tachycardia and conduction delays (widened QRS complex and/or prolonged QTc interval), not bradycardia or atrial fibrillation. 2
Among 116 patients with bupropion overdose, only 3 exhibited cardiotoxicity; all 3 experienced tachycardia and conduction delays, but none developed life-threatening arrhythmias. 2
All patients recovered with resolution of cardiotoxicity within 2-4 days. 2
Risk Factors for Adverse Cardiovascular Events
In a large cohort of 4,640 bupropion exposures, adverse cardiovascular events (vasopressor use, ventricular dysrhythmia, myocardial injury, or cardiac arrest) occurred in only 1.47% of patients and were associated with seizures, QRS widening, and QTc prolongation—not atrial fibrillation or bradycardia. 3
Age, single seizure (odds ratio 9.18), complicated seizures (odds ratio 38.9), QRS widening (odds ratio 3.01), and QTc prolongation (odds ratio 1.76) were independently associated with adverse cardiovascular events. 3
No patients with unintentional exposure experienced adverse cardiovascular events. 3
Maximum Dose and Safety Threshold
The maximum recommended dose of bupropion is 450 mg/day for the XL formulation and 400 mg/day for the SR formulation to maintain seizure risk at approximately 0.1%. 4
At doses ≤450 mg/day, the seizure rate is comparable to other antidepressants. 5
Bupropion is 10 to 100 times less likely to induce cardiac conduction problems than tricyclic antidepressants. 5
Monitoring Recommendations
Blood pressure and heart rate should be monitored periodically, especially during the first 12 weeks of treatment, as bupropion can cause elevations in both parameters. 4
- Uncontrolled hypertension is a contraindication for bupropion use. 4
Clinical Bottom Line
At 450 mg/day, bupropion does not cause atrial fibrillation or bradycardia. The primary cardiovascular concerns are hypertension and tachycardia, not rhythm disturbances. The evidence on bradycardia in the provided guidelines refers exclusively to antiarrhythmic drugs (amiodarone, sotalol, flecainide, propafenone) used to treat atrial fibrillation—not bupropion. 66
If a patient on bupropion 450 mg/day develops atrial fibrillation or bradycardia, investigate alternative causes rather than attributing these arrhythmias to bupropion.